sFcεRI as a potential biomarker for Endotypes of Chronic Urticaria (SECU)

• Applicant: Sherezade Moñino-Romero, Ph.D.
• Subject Area: Dermatology ; Clinical Immunology and Allergology
• Term: from 2022 to 2024
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 504179322

• Final Report Year: 2024

Final Report Abstract

1) sFcεRI is significantly elevated in serum of CSU patients. 2) sFcεRI might be used as a biomarker for type I autoallergic CSU, which could be beneficial for treating physicians to decide on therapy and monitor during treatment. 3) Human skin MCs are able to release sFcεRI only upon IgE-mediated activation in vitro and ex vivo. 4) Human skin MCs could be the source of serum sFcεRI levels in CSU. 5) Our findings on the cellular mechanisms of sFcεRI release and the use as a biomarker could contribute in the understanding of the pathomechanisms causing symptoms in CSU patients, and to identify good candidates for omalizumab treatment.

Publications

• Elevated baseline soluble FcεRI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 38(1), 167-174.
  Moñino‐Romero, S.; Kolkhir, P.; Ohanyan, T.; Szépfalusi, Z.; Weller, K.; Metz, M.; Scheffel, J.; Maurer, M. & Altrichter, S.
  
• In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria. Clinical and Translational Allergy, 13(7).
  Moñino‐Romero, Sherezade; Kolkhir, Pavel; Szépfalusi, Zsolt; Schoepke, Nicole; Metz, Martin; Asero, Riccardo; Ferrer, Marta; Gimenez‐Arnau, Ana; Grattan, Clive E. H.; Jakob, Thilo; Konstantinou, George N.; Raap, Ulrike; Staubach, Petra; Zhang, Ke; Bindslev‐Jensen, Carsten; Daschner, Alvaro; Kinaciyan, Tamar; Makris, Michael; Marrouche, Nadine ... & Altrichter, Sabine